Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 August 2024 | Story André Damons | Photo Supplied
Prof Patricks Voua Otomo
Prof Patricks Voua Otomo, Associate Professor and subject head of Department of Zoology and Entomology at the University of the Free State (UFS).

In an effort to alleviate the burden of water contamination, Prof Patricks Voua Otomo, Associate Professor in the Department of Zoology and Entomology at the University of the Free (UFS) is researching how mushrooms can be used to significantly reduce the toxicity of water.

The degradation of river systems in South Africa has been linked primarily to the inability of municipalities to properly treat wastewater. According to the 2022 Green Drop Report, out of the existing 850 wastewater systems across 90 municipalities, only 23 (or less than 3%) qualified for the Green Drop Certification. This underscores the depth and breadth of the wastewater treatment crisis in South Africa and its potential implications for human and environmental health.

In 2030, billions of people will still lack access to safe water, sanitation and hygiene services – the most basic human need for health and well-being. Target 6.1 of the United Nations (UN) Sustainable Development Goals (SDGs) – SDG 6 – aims to achieve universal and equitable access to safe and affordable drinking water for all, while target 6.3 is also looking to improve water quality by reducing pollution, eliminating dumping and minimising release of hazardous chemicals and materials, halving the proportion of untreated wastewater and substantially increasing recycling and safe re-use globally by 2030.

These challenges inform Prof Voua Otomo’s research, which focuses on the drivers of river pollution in the Qwaqwa region, ways to mitigate/remediate their effects, and the development of simple and quick methods to assess water quality. His research, which is part of the UFS 2023 Impact Report, has drawn attention to localised incidences of terrestrial and aquatic contamination linked to sewage sludge management by local wastewater treatment plants.

Using mycofiltration to reclaim the quality of contaminated water

In Qwaqwa, wastewater treatment plants, however, are not the only source of river pollution, as a significant amount of river pollutants emanates directly from the communities that often dispose of their household waste directly into the waterways. This has led to unacceptable levels of pharmaceuticals such as biphenyl-4-ylacetic acid (an anti-inflammatory), efavirenz (an HIV medicine), and carbamazepine (an epilepsy medicine) ending up in rivers.

To attempt to reclaim the quality of contaminated water, ongoing research in Prof Voua Otomo’s laboratory involves the use of ‘mycofiltration’, i.e., the use of fungal mycelia for the purpose of water filtration. This relatively untapped eco-friendly technology is attracting more attention, yet its real merits are only now being established and documented scientifically.

“Various species of fungi have been explored in bioremediation studies, and those belonging to the Pleurotus genus (edible mushrooms) have demonstrated an exceptional ability in the biosorption of contaminants,” says Prof Voua Otomo.

In his field of research, Prof Voua Otomo says snails can be used as bioindicators (i.e., organisms used to assess the health of an environment or ecosystem, particularly by indicating the presence and impact of pollutants or other environmental stressors) or biomonitors (i.e., organisms or a biological systems used to assess the health of an environment, particularly by detecting changes in the levels of pollutants or other harmful substances).

“We designed a mycofilter made of mycelia from the mushroom species Pleurotus ostreatus and filtrated water contaminated with the organic insecticide imidacloprid and the inorganic chemical iron (III). The results showed that mycofiltration could remove up to 94% of iron (III) and 31% of imidacloprid.

“Mycofiltration works through a process called adsorption, which is the process where molecules, ions, or particles from a gas, liquid, or dissolved solid, stick to a surface. This happens when the adsorbate (the substance being adsorbed) attaches to the adsorbent (the surface it adheres to),” Prof Voua Otomo explains.

Mycofiltration viable and affordable for water remediation

This research is the brainchild of Sanele Mnkandla, a final-year PhD student in Prof Voua Otomo’s laboratory. “A few years ago, she suggested looking at mycofiltration as a means to improve the quality of contaminated water. Freshwater snails were the most suitable organisms to help assess the improvement of the water quality after mycofiltration,” explains Prof Voua Otomo.

According to him, they are currently exploring ways to upscale the mycofilter to improve the quality of larger bodies of water, including rivers. The duration of the process depends on the size of the filter, the amount of water to be filtered and the targeted chemicals. Bigger filters, explains Prof Voua Otomo, will filter larger amounts of water over a relatively longer time whereas smaller ones will be saturated quickly. The process could last from minutes to days.

“We have published a technical note on the topic and a proof of concept. We are currently testing this technology using wastewater effluent in the Qwaqwa region. We are also exploring local applications in rainwater harvesting.

“Mycofiltration is certainly a viable and affordable option for water remediation, which can find a wide range of applications in South Africa,” he says. 

Watch the video below

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept